Novo Nordisk A/S

NOVO B

DK0062498333

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 07:23:05 2026-05-11 am EDT			5-day change	1st Jan Change
300.02 ^DKK	+3.35%		+7.05%	-6.87%

04:11am	Citi raises Novo Nordisk price target following strong Wegovy pill launch	FW
04:03am	SB1: Market underestimates Novo Nordisk potential - raises price target	FW

Citigroup trims Novo Nordisk price target to DKK 275 (309), reiterates Neutral - BN

Published on 04/17/2026 at 12:43 am EDT

Finwire - Translated by Marketscreener - See original

NOVO NORDISK A/S

+3.35%

Citigroup has lowered its price target for Novo Nordisk to DKK 275 from DKK 309, while maintaining its Neutral rating, according to Bloomberg News.

Latest news about Novo Nordisk A/S

04:11am	Citi raises Novo Nordisk price target following strong Wegovy pill launch	FW
04:03am	SB1: Market underestimates Novo Nordisk potential - raises price target	FW
02:14am	SB1 Markets raises Novo Nordisk price target to DKK 350 (280), reiterates Buy	FW
01:55am	Citigroup raises Novo Nordisk price target to DKK 290 (275), reiterates Neutral rating	FW
May. 08	Novo Nordisk sales surge in India following price cuts	FW
May. 08	Lilly's obesity pill tops 7,000 prescriptions in fourth week, signals modest uptake	RE
May. 08	NOVO NORDISK : Deutsche Bank gives a Neutral rating	ZD
May. 08	Novo Nordisk's Diabetes, Weight-Loss Drug Sales in India Rise After Price Cuts	MT
May. 08	NOVO NORDISK : Gets a Neutral rating from JP Morgan	ZD
May. 08	NOVO NORDISK : UBS sticks Neutral	ZD
May. 08	Novo Nordisk Sees 40% Jump in India Sales of Weight-Loss Drug After Price Cuts	MT
May. 08	NOVO NORDISK : Barclays sticks Neutral	ZD
May. 08	DZ Bank trims Novo Nordisk price target to DKK 299 (307), reiterates Hold - BN	FW
May. 08	Nykredit raises Novo Nordisk price target to DKK 350 (300), reiterates Buy - BN	FW
May. 07	Becton Dickinson raises 2026 profit forecast on drug delivery devices demand	RE

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (93.7%); - rare disease treatment products (6.3%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe and Canada (21.4%), the United States (56%), Latin America/Middle East/Africa (9.9%), China/Hong Kong/Taiwan (6%), Asia/Pacific (6.7%).

Employees

67,900

Sector

Pharmaceuticals

Calendar

Earnings release - Q2 2026

More about the company